Evotec stock ends the day near 52-week low at the close on Nasdaq
Published on 09/21/2026 at 23:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec stock, traded in the United States via Nasdaq-listed ADRs, ended the regular session on September 21, 2026 close to its 52-week low on the Nasdaq, with the ADR around USD 1.56 and down from a prior close near USD 1.60, implying a decline of roughly 2 to 4 percent for the day per U.S. venue data. Compared with a recent 52-week range that stretches from about USD 1.57 to USD 4.27, the closing level left the ADRs trading at the very bottom of their yearly corridor on the U.S. market.
September 21, 2026 in numbers
Evotec SE (ISIN DE0005664809, Nasdaq: EVO) reached a new 12-month low on Nasdaq during mid-day trading on September 21, 2026, with the ADRs touching an intraday low of USD 1.56 and last changing hands around USD 1.5550 on volume of just under 100,000 shares, after a prior U.S. close at USD 1.60, according to MarketBeat. On Xetra the home-market shares showed a different picture, with the stock around EUR 3.00 and up roughly 2.8 to 2.95 percent earlier in the day as Frankfurt trading delivered a technical rebound, per data cited by Ad-hoc-news; the difference between the home-market gains and the weak U.S. ADR reflects the exchange rate and the separate trading dynamics of the two venues.
The U.S.-listed ADRs around USD 1.56 remained far below their 52-week high near USD 4.27, signaling that even after the latest intraday moves the American instrument continues to price in heavy skepticism about the company and trades deep in the lower portion of its annual range per Nasdaq-oriented data summarized by Ad-hoc-news. In earlier commentary, deteriorating fundamentals, including a drop of nearly 20 percent in first-half 2026 revenue and a sharply negative adjusted EBITDA, were highlighted as key overhangs that continue to weigh on sentiment toward Evotec, as noted by Ground News, and these concerns framed the backdrop against which today’s U.S. price weakness unfolded.
After the bell and the next trading day
After the close on September 21, 2026, the extended session on Nasdaq continued to run until 8:00 p.m. ET, with the latest available indications keeping Evotec’s ADRs near their regular-session levels and still close to the new 12-month low flagged during mid-day trading, per the same MarketBeat alert. Investor calendars did not highlight a firm date for Evotec’s next quarterly or annual earnings release within the coming few trading days, so the next U.S. session on September 22, 2026 will likely see traders focus on how the ADRs trade relative to broader biotech benchmarks and sector peers, with the stock’s proximity to its 52-week low and the earlier home-market rebound in Frankfurt providing key reference points for short-term sentiment.
